Background: Papua New Guinea (PNG) has among the highest estimated burdens of cervical cancer globally but currently has no national cervical screening program. Visual inspection of the cervix with acetic acid (VIA) is a low-cost screening strategy endorsed by the World Health Organization that has been adopted in many low-resource settings but not previously evaluated in PNG. 
INTRODUCTION
Papua New Guinea (PNG) has among the highest estimated burdens of cervical cancer globally, with incidence 6.3 times that of Australia and New Zealand (age standardised rates 34.5 vs 5.5/100 000), and mortality 13.5 times greater (21.7 vs 1.6/100 000). 1, 2 Cervical cancer is the most common cancer among women in PNG and results in an estimated 1500 deaths per year. [1] [2] [3] There are currently no national programs for cervical cancer screening or human papillomavirus (HPV) vaccination in PNG. 3 and as specimens were sent to Australia for testing, up to half of those needing further investigation or treatment were lost to follow-up due to the time between testing and recall. 4 Consequently, in 2009 a Ministerial Task Force recommended that alternative, locally appropriate models of cervical screening and early treatment be evaluated in PNG. 5 The task force favoured the 'screen and treat' approach endorsed by the World Health Organization (WHO) 6 and based on visual inspection of the cervix with acetic acid (VIA) plus ablative cervical cryotherapy. 5 Favourable performance characteristics for the detection of histologically diagnosed cervical 'pre-cancer' (cervical intraepithelial neoplasia grade 2 or worse) in research settings 7 has led to VIA being advocated as an accurate, low-cost cervical screening strategy, and to its implementation in several low-and middle-income countries (LMICs).
However, many countries have experienced difficulties scaling up VIA while maintaining adequate quality, and have reported much lower sensitivity and specificity for the detection of cervical precancer compared to research settings.
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Here we report findings from the first evaluation of VIA for cervical screening in PNG. The primary objective was to evaluate the association between VIA examination findings and the presence of high-risk HPV (hrHPV) infection. Given earlier reports of high prevalence of genital sexually transmitted infections (STIs) among women attending antenatal, sexual health and Well
Woman Clinics in this setting [11] [12] [13] an additional objective was to evaluate the impact of concomitant STIs on interpretation of VIA examination findings. Systems, Pleasanton, CA, USA). 15, 16 Genital swabs were tested for C. trachomatis, N. gonorrhoeae and T. vaginalis by real-time polymerase chain reaction (PCR), using procedures and methods previously described. 17 The PNGIMR was enrolled in an ex- 
MATERIALS AND METHODS

Statistical considerations
Sample size requirements were based on a priori assumptions that the prevalence of hrHPV infection (all types, combined) would be around 10-15%; that around 10-15% of women would have a VIA positive women were more likely to be younger (<35 years) and to report a younger age of sexual debut (<18 years) than women with a negative VIA examination, but there was no association with reported lifetime number of sexual partners (Table 1) . 
Ethics approval
DISCUSSION
In this study among well women clinic attendees in PNG, VIA positivity was associated with HPV16 but not with other hrHPV infections, nor with genital C. trachomatis, N. gonorrhoeae or
T. vaginalis infection.
Our findings are consistent with earlier reports that HPV16 is associated with more definite visual abnormalities on VIA examination compared with other hrHPV types. 18 However, a recent prospective cohort study among 7541 women aged 25-65 years in rural China found that women who tested positive for any hrHPV infection were more likely to have a positive VIA examination than women who tested negative for hrHPV (15.0%, 95%CI:
12.9-17.2%; vs 6.3%, 95%CI: 5.7-6.9%; P < 0.001). 19 The authors also found an increasing probability of VIA being positive with increasing HPV viral load. 19 We postulated that the high prevalence of genital STIs in this setting would affect the performance of VIA because cervical infections might lead to acetowhite staining on VIA; and hypothesised that undiagnosed STIs may have undermined the performance of VIA following large-scale implementation in other low-resource settings. Cervical inflammation of unknown cause was present in 21.6% of 2331 women participating in a cervical screening program in Andhra Pradesh, India, and was associated with an increase in VIA positivity from 6.1% to 15.5% (P < 0.001) in the absence of histological evidence of cervical intraepithelial neoplasia. 20 A pilot study among 502 women in El Salvador found that women with cervicitis were twice as likely to have a positive VIA examination as women without cervicitis. 21 However, an earlier study among 2754 women in South Africa found no association between C. trachomatis or N. gonorrhoeae infection and VIA examination findings. 22 Given these conflicting findings, the relationship between cervical STIs and VIA examination may warrant further investigation. Such studies could also evaluate the role of the cervical infection Mycoplasma genitalium, which has not previously been described in this context. 3.0% (70/2338) had unsatisfactory VIA examinations (transformation zone not fully visualised, n = 11; cervicitis, n = 59). 23 A study among 45 000 women in Cameroon evaluated VIA enhanced by digital cervicography (VIA-DC) for cervical screening and found that 9.0% of women were VIA-DC positive; 66.8% were VIA-DC negative; 22.0%
were VIA-DC inadequate (cervix appeared normal but transformation zone not fully visualised); and 2.2% had uncertain examination findings due to concomitant cervical abnormalities confounding VIA-DC interpretation.
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In the last decade, the effectiveness of HPV-DNA based testing for the detection of cervical pre-cancer and cancer has been demonstrated in large-scale randomised trials and prospective studies, 25 leading to recommendations in Australia and other high-income settings for the introduction of HPV-DNA testing for primary cervical screening. [25] [26] [27] The WHO recently recommended that HPV-DNA testing be integrated into cervical screening programs in LMICs, but acknowledged that clinical algorithms based on VIA examination plus HPV testing require further evaluation. 28 The recent availability of a portable, highly accurate, easy-to-use, nucleic acid amplification TV, Trichomonas vaginalis. †No significant differences in hrHPV infection or other sexually transmitted infections were observed between women who did not undergo VIA and those having indeterminate VIA examination findings, and hence these groups were combined.
